High capacity protein purification for structural immunology
用于结构免疫学的高容量蛋白质纯化
基本信息
- 批准号:9309415
- 负责人:
- 金额:$ 7.69万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2016
- 资助国家:美国
- 起止时间:2016-05-01 至 2021-04-30
- 项目状态:已结题
- 来源:
- 关键词:AffinityAntigensAwardBinding ProteinsBiophysicsCD3 AntigensCellular ImmunityComputational TechniqueDataDevelopmentHealthImmuneImmune systemImmunityImmunologyImmunotherapyKnowledgeLearningMajor Histocompatibility ComplexMalignant NeoplasmsModelingMolecularMotionOutcomePeptide/MHC ComplexPeptidesPropertyProteinsRequest for ApplicationsResearchResearch PersonnelRoleShapesSignal TransductionSpecificityStructureT-Cell ReceptorT-LymphocyteT-Lymphocyte EpitopesTherapeuticTranslatingalpha-beta T-Cell Receptorbasecell mediated immune responsecomputerized toolscross reactivitydesignimmunoregulationimprovedmodel designmolecular recognitionprotein purificationrapid growthstructural biologysuccess
项目摘要
DESCRIPTION (provided by applicant): αβ T cell receptor (TCR) recognition of peptide antigens presented by major histocompatibility complex proteins (pMHC) is a cornerstone of cellular immunity, defining specificity and initiating the signaling that leads to T cell-mediated immune responses. Although data for TCR-pMHC interactions has increased significantly over the past decade, we still have a poor understanding of how T cells and TCRs achieve their extraordinary recognition properties. Nonetheless, there continues to be rapid growth in the use of TCRs and T cell epitopes for immunotherapy, particularly for cancer. While there have been immunotherapy successes, there have also been complications and setbacks. It is widely accepted that an improved understanding of TCR/T cell recognition is needed for such therapies to reach their potential. This proposal describes an ambitious, tightly integrated study that blends protein biophysics, structural biology, computation, and immunology to understand TCR recognition, signaling, and immune modulation. It also describes the development of general strategies for designing and improving immune-based therapeutics by incorporating advances in TCR recognition into efforts in computational design and modeling, and vice versa. Priorities include 1) determining how TCR-pMHC binding is shaped by evolutionary and non-evolutionary forces; 2) understanding the varied mechanisms underlying specificity and cross-reactivity in T cell recognition; 3) determining the role of molecular motion in TCR triggering, including the structural and dynamical properties of intact TCR/CD3 complexes; 4) learning how to design TCRs with improved molecular recognition properties, emphasizing antigen specificity and the ability to carefully modulate rather than simply enhance affinity; 5) developing computational techniques for high throughput modeling of TCR cross-reactivity and the structural/dynamical properties of neo-antigens in MHC proteins; and 6) learning how peptides alter MHC properties beyond those ascertainable from static structures and how this modulation impacts cellular immunity.
描述(由申请方提供):αβ T细胞受体(TCR)对主要组织相容性复合体蛋白(pMHC)呈递的肽抗原的识别是细胞免疫的基石,定义特异性并启动导致T细胞介导的免疫应答的信号传导。尽管在过去的十年中,TCR-pMHC相互作用的数据显著增加,但我们仍然对T细胞和TCR如何实现其非凡的识别特性知之甚少。尽管如此,TCR和T细胞表位用于免疫疗法,特别是用于癌症的免疫疗法的使用继续快速增长。虽然免疫疗法取得了成功,但也出现了并发症和挫折。人们普遍认为,需要对TCR/T细胞识别的更好理解,这样的疗法才能发挥其潜力。该提案描述了一项雄心勃勃的,紧密集成的研究,融合了蛋白质生物物理学,结构生物学,计算和免疫学,以了解TCR识别,信号传导和免疫调节。它还描述了通过将TCR识别的进展纳入计算设计和建模的努力中来设计和改进基于免疫的疗法的一般策略的发展,反之亦然。优先事项包括1)确定TCR-pMHC结合如何由进化和非进化力量形成; 2)理解T细胞识别中特异性和交叉反应性的不同机制; 3)确定分子运动在TCR触发中的作用,包括完整TCR/CD 3复合物的结构和动力学性质; 4)学习如何设计具有改进的分子识别特性的TCR,强调抗原特异性和仔细调节而不是简单地增强亲和力的能力; 5)开发用于TCR交叉反应性和MHC蛋白中新抗原的结构/动力学性质的高通量建模的计算技术;和6)了解肽如何改变MHC性质,而不是从静态结构中确定的性质,以及这种调节如何影响细胞免疫。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Brian M Baker其他文献
Peptide-dependent tuning of major histocompatibility complex motional properties and the consequences for cellular immunity
- DOI:
10.1016/j.coi.2022.102184 - 发表时间:
2022-06-01 - 期刊:
- 影响因子:5.800
- 作者:
Cory M Ayres;Brian M Baker - 通讯作者:
Brian M Baker
Brian M Baker的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Brian M Baker', 18)}}的其他基金
Mechanisms and manipulation of force dependent behavior in T cell biology
T 细胞生物学中力依赖性行为的机制和操纵
- 批准号:
10681766 - 财政年份:2023
- 资助金额:
$ 7.69万 - 项目类别:
Structural biophysics and molecular design in cellular immunity
细胞免疫中的结构生物物理学和分子设计
- 批准号:
9906945 - 财政年份:2016
- 资助金额:
$ 7.69万 - 项目类别:
Building better T cell receptors for targeted immunotherapy
为靶向免疫治疗构建更好的 T 细胞受体
- 批准号:
9388963 - 财政年份:2016
- 资助金额:
$ 7.69万 - 项目类别:
Building better T cell receptors for targeted immunotherapy
为靶向免疫治疗构建更好的 T 细胞受体
- 批准号:
10062838 - 财政年份:2016
- 资助金额:
$ 7.69万 - 项目类别:
Structural biophysics and molecular design in cellular immunity
细胞免疫中的结构生物物理学和分子设计
- 批准号:
10610363 - 财政年份:2016
- 资助金额:
$ 7.69万 - 项目类别:
Structural biophysics and molecular design in cellular immunity
细胞免疫中的结构生物物理学和分子设计
- 批准号:
10205576 - 财政年份:2016
- 资助金额:
$ 7.69万 - 项目类别:
Structural biophysics and molecular design in cellular immunity
细胞免疫中的结构生物物理学和分子设计
- 批准号:
9265480 - 财政年份:2016
- 资助金额:
$ 7.69万 - 项目类别:
Structural biophysics and molecular design in cellular immunity
细胞免疫中的结构生物物理学和分子设计
- 批准号:
9071715 - 财政年份:2016
- 资助金额:
$ 7.69万 - 项目类别:
Structural biophysics and molecular design in cellular immunity
细胞免疫中的结构生物物理学和分子设计
- 批准号:
10391537 - 财政年份:2016
- 资助金额:
$ 7.69万 - 项目类别:
相似国自然基金
Neo-antigens暴露对肾移植术后体液性排斥反应的影响及其机制研究
- 批准号:2022J011295
- 批准年份:2022
- 资助金额:10.0 万元
- 项目类别:省市级项目
结核分枝杆菌持续感染期抗原(latency antigens)的重组BCG疫苗研究
- 批准号:30801055
- 批准年份:2008
- 资助金额:19.0 万元
- 项目类别:青年科学基金项目
相似海外基金
Bovine herpesvirus 4 as a vaccine platform for African swine fever virus antigens in pigs
牛疱疹病毒 4 作为猪非洲猪瘟病毒抗原的疫苗平台
- 批准号:
BB/Y006224/1 - 财政年份:2024
- 资助金额:
$ 7.69万 - 项目类别:
Research Grant
A novel vaccine approach combining mosquito salivary antigens and viral antigens to protect against Zika, chikungunya and other arboviral infections.
一种结合蚊子唾液抗原和病毒抗原的新型疫苗方法,可预防寨卡病毒、基孔肯雅热和其他虫媒病毒感染。
- 批准号:
10083718 - 财政年份:2023
- 资助金额:
$ 7.69万 - 项目类别:
Small Business Research Initiative
Uncovering tumor specific antigens and vulnerabilities in ETP-acute lymphoblastic leukemia
揭示 ETP-急性淋巴细胞白血病的肿瘤特异性抗原和脆弱性
- 批准号:
480030 - 财政年份:2023
- 资助金额:
$ 7.69万 - 项目类别:
Operating Grants
Regulation of B cell responses to vaccines by long-term retention of antigens in germinal centres
通过在生发中心长期保留抗原来调节 B 细胞对疫苗的反应
- 批准号:
MR/X009254/1 - 财政年份:2023
- 资助金额:
$ 7.69万 - 项目类别:
Research Grant
Adaptive Discrimination of Risk of Antigens in Immune Memory Dynamics
免疫记忆动态中抗原风险的适应性辨别
- 批准号:
22KJ1758 - 财政年份:2023
- 资助金额:
$ 7.69万 - 项目类别:
Grant-in-Aid for JSPS Fellows
22-ICRAD Call 2 - Improving the diagnosis of tuberculosis in domestic ruminants through the use of new antigens and test platforms
22-ICRAD 呼吁 2 - 通过使用新抗原和测试平台改善家养反刍动物结核病的诊断
- 批准号:
BB/Y000927/1 - 财政年份:2023
- 资助金额:
$ 7.69万 - 项目类别:
Research Grant
Protective immunity elicited by distinct polysaccharide antigens of classical and hypervirulent Klebsiella
经典和高毒力克雷伯氏菌的不同多糖抗原引发的保护性免疫
- 批准号:
10795212 - 财政年份:2023
- 资助金额:
$ 7.69万 - 项目类别:
Integrative proteome analysis to harness humoral immune response against tumor antigens
综合蛋白质组分析利用针对肿瘤抗原的体液免疫反应
- 批准号:
23K18249 - 财政年份:2023
- 资助金额:
$ 7.69万 - 项目类别:
Grant-in-Aid for Challenging Research (Exploratory)
Targeting T3SA proteins as protective antigens against Yersinia
将 T3SA 蛋白作为针对耶尔森氏菌的保护性抗原
- 批准号:
10645989 - 财政年份:2023
- 资助金额:
$ 7.69万 - 项目类别:
Functionally distinct human CD4 T cell responses to novel evolutionarily selected M. tuberculosis antigens
功能独特的人类 CD4 T 细胞对新型进化选择的结核分枝杆菌抗原的反应
- 批准号:
10735075 - 财政年份:2023
- 资助金额:
$ 7.69万 - 项目类别: